brentie and HHIGambler, These are the slides. H
Post# of 148109
(Total Views: 486)
Posted On: 12/25/2022 9:42:06 PM
brentie and HHIGambler,
These are the slides. HH referenced slide 52 and brentie slide 53. The audio from these two slides is confusing.
On the left side of slide 52 we’re talking about Treatment Emergent and Treatment Related Adverse Events. The right side of slide 52 shows Serious Adverse Events and shows 1 related to treatment.
Slide 53 goes into more detail about the left side of slide 52 - TEAE and TRAE. Slide 53 makes no mention of the SAE from the right side of slide 52.
Interesting slide 53 in entitled “Safety Data: Top 13 treatment related TEAEs” So which is it? Treatment related or treatment emergent? Perhaps a treatment related outcome by necessity has ‘emerged’ after treatment has begun and by extension a treatment related event is a degree further along the timeline of a treatment emergent event. In other words, it can’t be related until after treatment has emerged. Anyhoo.
I apologize for saying anything about an SAE of 1. I was exactly misremembering the 1 TREA after emergence of treatment shown in slide 53 underneath the little black arrow near the right. It was a category 3-4 TRAE. It has a little title that says “Only Leronlimab related Grade 3-4.”
I shouldn’t have said SAE. Interestingly though, in slide 52 on the right side, Cyrus clearly presents 1 SAE. But never describes it further in either audio or in a following slide. In slide 52 it’s clearly described as an, “SAE related to treatment.”
Hope this provides some clarity. Sorry to have misremembered. There are certainly flaws in my methodology, and I’m okay with that. Not investment advice.
These are the slides. HH referenced slide 52 and brentie slide 53. The audio from these two slides is confusing.
On the left side of slide 52 we’re talking about Treatment Emergent and Treatment Related Adverse Events. The right side of slide 52 shows Serious Adverse Events and shows 1 related to treatment.
Slide 53 goes into more detail about the left side of slide 52 - TEAE and TRAE. Slide 53 makes no mention of the SAE from the right side of slide 52.
Interesting slide 53 in entitled “Safety Data: Top 13 treatment related TEAEs” So which is it? Treatment related or treatment emergent? Perhaps a treatment related outcome by necessity has ‘emerged’ after treatment has begun and by extension a treatment related event is a degree further along the timeline of a treatment emergent event. In other words, it can’t be related until after treatment has emerged. Anyhoo.
I apologize for saying anything about an SAE of 1. I was exactly misremembering the 1 TREA after emergence of treatment shown in slide 53 underneath the little black arrow near the right. It was a category 3-4 TRAE. It has a little title that says “Only Leronlimab related Grade 3-4.”
I shouldn’t have said SAE. Interestingly though, in slide 52 on the right side, Cyrus clearly presents 1 SAE. But never describes it further in either audio or in a following slide. In slide 52 it’s clearly described as an, “SAE related to treatment.”
Hope this provides some clarity. Sorry to have misremembered. There are certainly flaws in my methodology, and I’m okay with that. Not investment advice.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼